Cited by 196Metabolism and Genetic DisordersAmino Acid Enzymes and MetabolismLysosomal Storage Disorders Research

Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study

Trefz, Friedrich K., Burton, Barbara K., Longo, Nicola, Casanova, Mercedes Martinez-Pardo, Gruskin, Daniel J., Dorenbaum, Alex, Kakkis, Emil D., Crombez, Eric A. +11 more·2009·The Journal of Pediatrics

Abstract

Objective To evaluate the ability of sapropterin dihydrochloride (pharmaceutical preparation of tetrahydrobiopterin) to increase phenylalanine (Phe) tolerance while maintaining adequate blood Phe control in 4- to 12-year-old children with phenylketonuria (PKU).Study design This international, double-blind, randomized, placebo-controlled study screened for sapropterin response among 90 enrolled subjects in Part 1. In Part 2, 46 responsive subjects with PKU were randomized (3:1) to sapropterin, 20 mg/kg/d, or placebo for 10 weeks while continuing on a Phe-restricted diet. After 3 weeks, a dietary Phe supplement was added every 2 weeks if Phe control was adequate.Results The mean (+/-SD) Phe supplement tolerated by the sapropterin group had increased significantly from the pretreatment amount (0 mg/kg/d) to 20.9 (+/-15.4) mg/kg/d (P < .001) at the last visit at which subjects had adequate blood Phe control (<360 micromol/L), up to week 10. Over the 10-week period, the placebo group tolerated only an additional 2.9 (+/-4.0) mg/kg/d Phe supplement; the mean difference from the sapropterin group (+/-SE) was 17.7 +/- 4.5 mg/kg/d (P < .001). No severe or serious related adverse events were observed.Conclusions Sapropterin is effective in increasing Phe tolerance while maintaining blood Phe control and has an acceptable safety profile in this population of children with PKU.

Integrity signals

Registry

Crossref · 10.1016/j.jpeds.2008.11.040

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Sapropterin is the first non-dietary FDA-approved synthetic BH4 for phenylketonuria and lowers blood phenylalanine by stabilizing and increasing PAH activity.

    “Sapropterin (Kuvan) is the first non-dietary, FDA-approved, synthetic form of BH4 for patients with phenylketonuria that is effective in lowering blood Phen levels by stabilizing and increasing PAH activity”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Trefz, F. K., Burton, B. K., Longo, N., Casanova, M. M.-P., Gruskin, D. J., Dorenbaum, A., Kakkis, E. D., Crombez, E. A., Grange, D. K., Harmatz, P., Lipson, M. H., Milanowski, A., Randolph, L. M., Vockley, J., Whitley, C. B., Wolff, J. A., Bebchuk, J., Christ-Schmidt, H., & Hennermann, J. B.
Affiliations
  • Kreiskliniken Reutlingen (DE)
  • Lurie Children's Hospital (US)
  • University of Utah (US)
  • Emory University (US)
  • BioMarin (United States) (US)
  • University of California, Los Angeles (US)
  • Washington University in St. Louis (US)
  • UCSF Benioff Children's Hospital (US)
  • Kaiser Permanente (US)
  • Instytut Matki i Dziecka (PL)
  • University of Southern California (US)
  • University of Pittsburgh (US)
  • University of Minnesota (US)
  • University of Wisconsin–Madison (US)
  • Statistics Collaborative (US)
  • Charité – Universitätsmedizin Berlin (DE)
Corresponding author
Trefz, Friedrich K.
Venue
The Journal of Pediatrics
Publisher
Elsevier BV
Published
2009-05
Volume
154
Issue
5
Pages
700-707.e1
ISSN
0022-3476 (ISSN-L)
OpenAlex
W2037047569
Cited by
196
References
37
Citations by year
2026: 6 · 2025: 6 · 2024: 8 · 2023: 11 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 13 · 2018: 11 · 2017: 10 · 2016: 5 · 2015: 19 · 2014: 9 · 2013: 11 · 2012: 21
FWCI
14.70
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Pediatrics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
Keywords
sapropterin dihydrochloride, phenylketonuria, phenylalanine tolerance, tetrahydrobiopterin, children, phenylalanine-restricted diet, drug safety and efficacy
MeSH terms
Algorithms, Biopterins, Child, Child, Preschool, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Phenylalanine, Phenylketonurias, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review